Triple-Negative Breast Cancer Latest Advances

Find the Latest Research About Triple-Negative Breast Cancer

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4125 publications

Ultrasound-targeted microbubble cavitation enhances anti-PD-L1 therapy in TNBC via eNOS-mediated reoxygenation.

Ultrasound-targeted microbubble cavitation enhances anti-PD-L1 therapy in TNBC via eNOS-mediated reoxygenation.

Journal: JCI insight
Published: April 07, 2026

Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC.

Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC.

Journal: Science advances
Published: April 03, 2026

Mitochondrial protein translation is a heightened dependence and therapeutic vulnerability of chemo-refractory triple negative breast cancer.

Mitochondrial protein translation is a heightened dependence and therapeutic vulnerability of chemo-refractory triple negative breast cancer.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Correction to 'Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment'.

Correction to 'Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment'.

Journal: Journal of extracellular vesicles
Published: April 01, 2026

CRE26-067: Treatment Response to Lenvatinib in Metastatic Adenoid Cystic Triple Negative Breast Cancer: A Case Report.

CRE26-067: Treatment Response to Lenvatinib in Metastatic Adenoid Cystic Triple Negative Breast Cancer: A Case Report.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

Correction to "Ferroptosis Induction by a New Pyrrole Derivative in Triple Negative Breast Cancer and Colorectal Cancer".

Correction to "Ferroptosis Induction by a New Pyrrole Derivative in Triple Negative Breast Cancer and Colorectal Cancer".

Journal: Journal of medicinal chemistry
Published: March 25, 2026

Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC.

Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC.

Journal: Journal of medicinal chemistry
Published: March 23, 2026

Machine learning-driven drug discovery for the management of TNBC: focus on IDO1 and TDO targets.

Machine learning-driven drug discovery for the management of TNBC: focus on IDO1 and TDO targets.

Journal: SAR and QSAR in environmental research
Published: March 17, 2026

Correlation of STAT6 and HER2-low expression with clinicopathological features and prognosis in triple negative breast cancer

Correlation of STAT6 and HER2-low expression with clinicopathological features and prognosis in triple negative breast cancer

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: March 08, 2026

Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Journal: Journal of medicinal chemistry
Published: March 07, 2026

Personalized mRNA Vaccine Spurs Lasting Immunity in TNBC.

Personalized mRNA Vaccine Spurs Lasting Immunity in TNBC.

Journal: Cancer discovery
Published: February 27, 2026

ASO Visual Abstract: Differences in Treatment and Survival for Secondary Triple Negative Breast Cancer in Premenopausal Women.

ASO Visual Abstract: Differences in Treatment and Survival for Secondary Triple Negative Breast Cancer in Premenopausal Women.

Journal: Annals of surgical oncology
Published: February 24, 2026
Showing 1-12 of 4,125

Last Updated: 04/28/2026